Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 254

1.

Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib.

Cabezas-Camarero S, Puente J, Manzano A, Corona JA, González-Larriba JL, Bernal-Becerra I, Sotelo M, Díaz-Rubio E.

Anticancer Drugs. 2014 Jul 29. [Epub ahead of print]

PMID:
25075797
[PubMed - as supplied by publisher]
2.

Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists.

Camps-Herrero C, Paz-Ares L, Codes M, López-López R, Antón-Torres A, Gascón-Vilaplana P, Guillem-Porta V, Carrato A, Cruz-Hernández JJ, Caballero-Díaz C, Blasco-Cordellat A, Moreno-Nogueira JA, Díaz-Rubio E.

Clin Transl Oncol. 2014 Oct;16(10):914-20. doi: 10.1007/s12094-014-1170-1. Epub 2014 Jun 13.

PMID:
24924625
[PubMed - in process]
3.

Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?

Aguado C, García-Paredes B, Sotelo MJ, Sastre J, Díaz-Rubio E.

World J Gastroenterol. 2014 May 28;20(20):6092-101. doi: 10.3748/wjg.v20.i20.6092.

PMID:
24876731
[PubMed - in process]
Free PMC Article
4.

BRCA2 gene: a candidate for clinical testing in familial colorectal cancer type X.

Garre P, Martín L, Sanz J, Romero A, Tosar A, Bando I, Llovet P, Diaque P, García-Paredes B, Díaz-Rubio E, de la Hoya M, Caldés T.

Clin Genet. 2014 May 12. doi: 10.1111/cge.12427. [Epub ahead of print]

PMID:
24814045
[PubMed - as supplied by publisher]
5.

Role of cetuximab in first-line treatment of metastatic colorectal cancer.

Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E.

World J Gastroenterol. 2014 Apr 21;20(15):4208-19. doi: 10.3748/wjg.v20.i15.4208.

PMID:
24764659
[PubMed - in process]
Free PMC Article
6.

TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J, García-Foncillas J, Grávalos C, Laquente B, Pericay C, Rivera F, Tabernero J, Aranda E.

Clin Transl Oncol. 2014 Oct;16(10):865-78. doi: 10.1007/s12094-014-1177-7. Epub 2014 Apr 12.

PMID:
24728654
[PubMed - in process]
7.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S.

Lancet Oncol. 2014 Apr;15(4):406-14. doi: 10.1016/S1470-2045(14)70069-5. Epub 2014 Mar 11.

PMID:
24636208
[PubMed - indexed for MEDLINE]
8.

Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium.

Colombo M, Blok MJ, Whiley P, Santamariña M, Gutiérrez-Enríquez S, Romero A, Garre P, Becker A, Smith LD, De Vecchi G, Brandão RD, Tserpelis D, Brown M, Blanco A, Bonache S, Menéndez M, Houdayer C, Foglia C, Fackenthal JD, Baralle D, Wappenschmidt B; kConFaB Investigators, Díaz-Rubio E, Caldés T, Walker L, Díez O, Vega A, Spurdle AB, Radice P, De La Hoya M.

Hum Mol Genet. 2014 Jul 15;23(14):3666-80. doi: 10.1093/hmg/ddu075. Epub 2014 Feb 25.

PMID:
24569164
[PubMed - in process]
9.

Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity.

Fernández-Marcelo T, Frías C, Pascua I, de Juan C, Head J, Gómez A, Hernando F, Jarabo JR, Díaz-Rubio E, Torres AJ, Rouleau M, Benito M, Iniesta P.

J Exp Clin Cancer Res. 2014 Feb 15;33:19. doi: 10.1186/1756-9966-33-19.

PMID:
24528514
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Oncological translational research in the Spanish national health system: the INTRO study.

Caballero C, Jantus-Lewintre E, Carrato A, García-Foncillas J, Gascón P, Blasco A, Moreno-Nogueira JA, Guillem V, López R, Codes M, Antón A, Díaz-Rubio E, Camps C.

Clin Transl Oncol. 2014 Aug;16(8):686-95. doi: 10.1007/s12094-013-1138-6. Epub 2013 Dec 5.

PMID:
24307394
[PubMed - in process]
11.

About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.

Gutiérrez-Enríquez S, Bonache S, de Garibay GR, Osorio A, Santamariña M, Ramón y Cajal T, Esteban-Cardeñosa E, Tenés A, Yanowsky K, Barroso A, Montalban G, Blanco A, Cornet M, Gadea N, Infante M, Caldés T, Díaz-Rubio E, Balmaña J, Lasa A, Vega A, Benítez J, de la Hoya M, Diez O.

Int J Cancer. 2014 May 1;134(9):2088-97.

PMID:
24130102
[PubMed - indexed for MEDLINE]
12.

Capillary electrophoresis analysis of conventional splicing assays: IARC analytical and clinical classification of 31 BRCA2 genetic variants.

de Garibay GR, Acedo A, García-Casado Z, Gutiérrez-Enríquez S, Tosar A, Romero A, Garre P, Llort G, Thomassen M, Díez O, Pérez-Segura P, Díaz-Rubio E, Velasco EA, Caldés T, de la Hoya M.

Hum Mutat. 2014 Jan;35(1):53-7. doi: 10.1002/humu.22456. Epub 2013 Oct 28.

PMID:
24123850
[PubMed - indexed for MEDLINE]
13.

Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer.

Garre P, Martín L, Bando I, Tosar A, Llovet P, Sanz J, Romero A, de la Hoya M, Díaz-Rubio E, Caldés T.

Fam Cancer. 2014 Mar;13(1):109-19. doi: 10.1007/s10689-013-9683-2.

PMID:
24061861
[PubMed - in process]
14.

Frequency and variability of genomic rearrangements on MSH2 in Spanish Lynch Syndrome families.

Romero A, Garre P, Valentin O, Sanz J, Pérez-Segura P, Llovet P, Díaz-Rubio E, de la Hoya M, Caldés T.

PLoS One. 2013 Sep 11;8(9):e72195. doi: 10.1371/journal.pone.0072195. eCollection 2013.

PMID:
24039744
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection.

Romero A, Prat A, García-Sáenz JA, Del Prado N, Pelayo A, Furió V, Román JM, de la Hoya M, Díaz-Rubio E, Perou CM, Cladés T, Martín M.

Clin Transl Oncol. 2014 Apr;16(4):386-94. doi: 10.1007/s12094-013-1088-z. Epub 2013 Aug 2.

PMID:
23907291
[PubMed - in process]
16.

Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer.

Martín M, Custodio S, de Las Casas ML, García-Sáenz JÁ, de la Torre JC, Bellón-Cano JM, López-Tarruella S, Vidaurreta-Lazaro M, de la Orden V, Jerez Y, Márquez-Rodas I, Casado A, Sastre J, Díaz-Rubio E.

Oncologist. 2013;18(8):917-23. doi: 10.1634/theoncologist.2012-0479. Epub 2013 Jul 19.

PMID:
23873719
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.

Zugazagoitia J, Puente J, González-Larriba JL, Manzano A, Sotelo M, Hernández S, Sanz J, Pérez P, Díaz-Rubio E.

Oncology. 2013;84(5):255-64. doi: 10.1159/000346534. Epub 2013 Feb 20.

PMID:
23428780
[PubMed - indexed for MEDLINE]
18.

[New strategies to improve accessibility to laboratory tests in cancer patients].

Cuadrado-Cenzual MÁ, García-Saenz JÁ, López Palacios S, de Pedro Moro JA, Díaz-Rubio E.

Rev Calid Asist. 2013 Jul-Aug;28(4):217-23. doi: 10.1016/j.cali.2012.11.003. Epub 2013 Jan 5. Spanish.

PMID:
23298729
[PubMed - indexed for MEDLINE]
19.

Low prevalence of SLX4 loss-of-function mutations in non-BRCA1/2 breast and/or ovarian cancer families.

de Garibay GR, Díaz A, Gaviña B, Romero A, Garre P, Vega A, Blanco A, Tosar A, Díez O, Pérez-Segura P, Díaz-Rubio E, Caldés T, de la Hoya M.

Eur J Hum Genet. 2013 Aug;21(8):883-6. doi: 10.1038/ejhg.2012.268. Epub 2012 Dec 5.

PMID:
23211700
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

PLoS One. 2012;7(10):e47345. doi: 10.1371/journal.pone.0047345. Epub 2012 Oct 12.

PMID:
23174912
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk